The Outcome of Prolactinoma in the Postpartum Period: a Study from a Tertiary Care Hospital in Pakistan

a study from a tertiary care hospital in Pakistan


  • Shirin Gul Suhail Department of Obstetrics & Gynecology Avicenna Medical College, Lahore
  • Omair Afzal
  • Zahra Safdar
  • Rizwan Ahmad Khan
  • Uzma Zia



Prolactinomas, pregnancy, serum prolactin, lactation, Cabergoline.


Objective:  Prolactin is an essential hormone secreted by the pituitary gland of pregnant women. The pituitary gland undergoes growth, due to lactotroph hyperplasia in response to placental estrogen during pregnancy. Research on the postpartum outcomes of prolactinomas is less. This study evaluates the prevalence of Prolactinoma and the occurrence of spontaneous resolution of Prolactinomas after pregnancy.

Materials and Methods:  A cross-section study was conducted at the Punjab Institute of Neurosciences, Lahore. 200 pregnant women were recruited; their blood samples were collected to evaluate serum prolactin levels. Women diagnosed with prolactinomas exhibiting positive symptoms were given dopamine agonists. The administration of dopamine agonist was discontinued at the 24th week of gestation. All participants were monitored till birth, at 40 days after delivery, and throughout breastfeeding. Their prolactin levels were evaluated, and magnetic resonance imaging (MRI) was conducted to verify the resolution of prolactinoma.

Results:  The mean age of females in the study was 29.03 ± 7.20 years. Out of 200, 40 (20%) females had prolactinoma. Out of 40, 13 (32.5%) were given Bromocriptine while 27 (67.5%) were given Cabergoline. At presentation, the mean serum prolactin level was 138.91 ± 149.02 ng/ml, which reduced to 21.38 ± 9.80 ng/ml. The mean tumor size at presentation was 7.23 ± 2.07 mm, which reduced to 0.79 ± 0.66 mm after delivery. Out of 40, 30 (75.0%) had spontaneous resolution.

Conclusion:  The occurrence of prolactinoma is low in symptomatic patients and can resolve spontaneously after delivery in the majority of cases.


Chanson P, Maiter D. The epidemiology, diagnosis and treatment of Prolactinomas: The old and the new. Best practice & research Clinical endocrinology & metabolism. 2019;33(2):101290.

Jin Y, Fan M. Treatment of gynecomastia with prednisone: case report and literature review. The Journal of international medical research. 2019;47(5):2288-95.

Woodmansee WW. Pituitary disorders in pregnancy. Neurologic clinics. 2019;37(1):63-83.

Chrisoulidou A, Boudina M, Karavitaki N, Bill E, Wass J. Pituitary disorders in pregnancy. Hormones. 2015;14(1):70-80.

Li H, Huang Y, Li Y, Zheng B, Cui J, Liu M. Endocrine Manifestations in POEMS Syndrome: a case report and literature review. BMC endocrine disorders. 2019;19(1):33.

Valassi E. Pituitary disease and pregnancy. Endocrinología, Diabetes y Nutrición (English ed). 2021;68(3):184-95.

Nagaishi VS, Cardinali LI, Zampieri TT, Furigo IC, Metzger M, Donato Jr J. Possible crosstalk between leptin and prolactin during pregnancy. Neuroscience. 2014;259:71-83.

Yip SH, Romano N, Gustafson P, Hodson DJ, Williams EJ, Kokay IC, et al. Elevated prolactin during pregnancy drives a phenotypic switch in mouse hypothalamic dopaminergic neurons. Cell reports. 2019;26(7):1787-99. e5.

Laway BA, Baba MS, Bansiwal SK, Choh NA. Prolactinoma Outcome After Pregnancy and Lactation: A Cohort Study. Indian Journal of Endocrinology and Metabolism. 2021;25(6):559.

Melmed S, Casanueva FF, Hoffman AR, Kleinberg DL, Montori VM, Schlechte JA, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. The Journal of clinical endocrinology and metabolism. 2011;96(2):273-88.

Thapa S, Bhusal K. Hyperprolactinemia. 2019.

Araujo B, Belo S, Carvalho D. Pregnancy and tumor outcomes in women with prolactinoma. Experimental and Clinical Endocrinology & Diabetes. 2017;125(10):642-8.

Rastogi A, Bhadada SK, Bhansali A. Pregnancy and tumor outcomes in infertile women with macroprolactinoma on cabergoline therapy. Gynecological Endocrinology. 2017;33(4):270-3.

Chahal J, Schlechte J. Hyperprolactinemia. Pituitary. 2008;11(2):141-6.

Bernard V, Young J, Binart N. Prolactin – a pleiotropic factor in health and disease. Nature reviews Endocrinology. 2019;15(6):356-65.

Irfan H, Shafiq W, Siddiqi AI, Ashfaq S, Attaullah S, Munir Alvi A, et al. Prolactinoma: Clinical Characteristics, Management and Outcome. Cureus. 2022;14(10):e29822.

Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. New England Journal of Medicine. 2003;349(21):2023-33.

Auriemma RS, Perone Y, Di Sarno A, Grasso LF, Guerra E, Gasperi M, et al. Results of a single-center observational 10-year survey study on recurrence of hyperprolactinemia after pregnancy and lactation. The Journal of Clinical Endocrinology & Metabolism. 2013;98(1):372-9.

Almalki MH, Alzahrani S, Alshahrani F, Alsherbeni S, Almoharib O, Aljohani N, et al. Managing Prolactinomas during Pregnancy. Frontiers in Endocrinology. 2015;6.

Shahzad H, Sheikh A, Sheikh L. Cabergoline therapy for macroprolactinoma during pregnancy: a case report. BMC research notes. 2012;5(1):1-4.

Webster J. A comparative review of the tolerability profiles of dopamine agonists in the treatment of hyperprolactinaemia and inhibition of lactation. Drug safety. 1996;14:228-38.

Andersen A-MN, Wohlfahrt J, Christens P, Olsen J, Melbye M. Maternal age and fetal loss: population based register linkage study. Bmj. 2000;320(7251):1708-12.

Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocrine reviews. 2006;27(5):485-534.